Logo image
Emerging and future therapies for hemophilia
Journal article   Open access   Peer reviewed

Emerging and future therapies for hemophilia

Marcus E Carr and Bartholomew J Tortella
Journal of blood medicine, v 6, pp 245-255
03 Sep 2015
PMID: 26366108
url
https://doi.org/10.2147/jbm.s42669View
Published, Version of Record (VoR)CC BY-NC V4.0 Open
url
https://doi.org/10.2147/JBM.S42669View
Published, Version of Record (VoR) Open

Abstract

anti-tissue factor pathway inhibitor antibodies clotting factor analogs extended half-life clotting factors gene therapy nonfactor replacement therapy Review
The evolution of care in hemophilia is a remarkable story. Over the last 60 years, advances in protein purification, protein chemistry, donor screening, viral inactivation, gene sequencing, gene cloning, and recombinant protein production have dramatically enhanced the treatment and lives of patients with hemophilia. Recent efforts have produced enhanced half-life (EHL) clotting factors to better support prophylaxis and decrease the frequency of infusions. Medical needs remain in the areas of alternate modes of administration to decrease the need for venous access, better treatment, and prophylaxis for patients who form antibodies to clotting factors, and ultimately a cure of the underlying genetic defect. In this brief review, the authors summarize data on EHL clotting factors, introduce agents whose mode of action is not clotting factor replacement, and list current gene therapy efforts.

Metrics

20 Record Views
27 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Industry collaboration
Domestic collaboration
Web of Science research areas
Hematology
Logo image